Hailemichael O Yosief
Overview
Explore the profile of Hailemichael O Yosief including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muthengi A, Wimalasena V, Yosief H, Bikowitz M, Sigua L, Wang T, et al.
J Med Chem
. 2021 Apr;
64(9):5787-5801.
PMID: 33872011
The use of epigenetic bromodomain inhibitors as anticancer therapeutics has transitioned from targeting bromodomain extraterminal domain (BET) proteins into targeting non-BET bromodomains. The two most relevant non-BET bromodomain oncology targets...
2.
Hussain S, Sarker M, Yosief H
Arch Microbiol
. 2020 Oct;
203(2):629-634.
PMID: 33006037
This investigation assessed the synergistic effectiveness of alkyltrimethylammonium bromide (ATMB) and chlorhexidine digluconate (CDG) on selected microbes causing red-heat and purple stain degradations on salt-cured hides and leather products. This...
3.
Zhou D, Hayashi T, Jean M, Kong W, Fiches G, Biswas A, et al.
Sci Adv
. 2020 Aug;
6(29):eaba1941.
PMID: 32832623
Although combination antiretroviral therapy is effective in controlling HIV-1 infection, latent HIV-1 proviruses cannot be eliminated. HIV-1 reactivation induced by the mere use of latency-reversing agents is insufficient to render...
4.
Timme N, Han Y, Liu S, Yosief H, Dorado Garcia H, Bei Y, et al.
Transl Oncol
. 2019 Dec;
13(2):221-232.
PMID: 31869746
Simultaneous inhibition of multiple molecular targets is an established strategy to improve the continuance of clinical response to therapy. Here, we screened 49 molecules with dual nanomolar inhibitory activity against...
5.
Liu S, Yosief H, Dai L, Huang H, Dhawan G, Zhang X, et al.
J Med Chem
. 2018 Aug;
61(17):7785-7795.
PMID: 30125504
The simultaneous inhibition of polo-like kinase 1 (PLK1) and BRD4 bromodomain by a single molecule could lead to the development of an effective therapeutic strategy for a variety of diseases...
6.
Huang H, Liu S, Jean M, Simpson S, Huang H, Merkley M, et al.
Front Microbiol
. 2017 Jun;
8:1035.
PMID: 28638377
While combinatory antiretroviral therapy (cART) can effectively reduce HIV-1 viremia, it cannot eliminate HIV-1 infection. In the presence of cART, viral reservoirs remain latent, impeding the cure of HIV-1/AIDS. Recently,...
7.
Yosief H, Iyer S, Weiss A
Infect Immun
. 2013 May;
81(8):2753-60.
PMID: 23690406
The two major forms of Shiga toxin, Stx1 and Stx2, use the glycolipid globotriaosylceramide (Gb3) as their cellular receptor. Stx1 primarily recognizes the Pk-trisaccharide portion and has three Pk binding...
8.
Yosief H, Weiss A, Iyer S
Chembiochem
. 2013 Jan;
14(2):251-9.
PMID: 23307594
Biotinylated mono- and biantennary di-/trisaccharides were synthesized to evaluate their ability to capture E. coli strains that express pilus types with different receptor specificities. The synthesized biotinylated di-/trisaccharides contain Galα(1→4)Gal,...